Copper supplementation of adult men: effects on blood copper enzyme activities and indicators of cardiovascular disease risk

What Was Tested

The paper reports a study of Copper (Supplement), published as a randomized controlled trial.

In rats, copper deficiency leads to low copper metalloenzyme activity, high serum cholesterol, and cardiovascular lesions.

In humans, moderately low copper intake may be common, but the consequences remain largely uncertain.

Who Took Part

According to the abstract, 20 men were involved.

PubMed indexes the participants as adults and middle-aged adults, men only.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got Copper (Supplement) and who got the comparison, which limits bias.

Neither the men nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.

Some men received a placebo instead of Copper (Supplement), giving a reference point.

In the crossover set-up each of the men took both Copper (Supplement) and the comparison in turn, acting as their own control.

The timeline in the abstract includes 4 weeks.

What Was Measured

PubMed files the paper under topics including Amine Oxidase (Copper-Containing), Cardiovascular Diseases, Ceruloplasmin, Cholesterol, Copper, Erythrocytes and Lipid Peroxidation.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement) in 20 men over 4 weeks.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1997 (Metabolism: clinical and experimental), a journal based in United States.

More context: the Copper (Supplement) compound page, all human trials.